Twist Bioscience Co. (NASDAQ:TWST) Insider Sells $14,188.40 in Stock

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) insider Dennis Cho sold 316 shares of the business's stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $44.90, for a total value of $14,188.40. Following the sale, the insider now directly owns 113,171 shares of the company's stock, valued at $5,081,377.90. This represents a 0.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Dennis Cho also recently made the following trade(s):

• On Monday, December 16th, Dennis Cho sold 133 shares of Twist Bioscience stock. The stock was sold at an average price of $46.81, for a total transaction of $6,225.73.
• On Friday, December 6th, Dennis Cho sold 367 shares of Twist Bioscience stock. The shares were sold at an average price of $52.70, for a total value of $19,340.90.
• On Monday, November 11th, Dennis Cho sold 1,507 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total value of $72,336.00.
• On Monday, November 4th, Dennis Cho sold 659 shares of Twist Bioscience stock. The stock was sold at an average price of $41.56, for a total value of $27,388.04.
• On Wednesday, October 2nd, Dennis Cho sold 3,104 shares of Twist Bioscience stock. The shares were sold at an average price of $43.21, for a total value of $134,123.84.

Twist Bioscience Stock Performance

Twist Bioscience stock traded up $0.32 during mid-day trading on Thursday, reaching $49.22. The company's stock had a trading volume of 486,879 shares, compared to its average volume of 940,682. The business's 50 day simple moving average is $45.51 and its 200 day simple moving average is $46.72. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90. The company has a market capitalization of $2.92 billion, a price-to-earnings ratio of -13.67 and a beta of 1.82.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on TWST. Scotiabank boosted their price objective on shares of Twist Bioscience from $50.00 to $54.00 and gave the company a "sector outperform" rating in a report on Tuesday, November 19th. Wolfe Research assumed coverage on Twist Bioscience in a research note on Friday, December 13th. They issued an "outperform" rating and a $60.00 target price for the company. Leerink Partners raised their price target on Twist Bioscience from $45.00 to $48.00 and gave the stock a "market perform" rating in a research report on Thursday, October 17th. Robert W. Baird increased their target price on Twist Bioscience from $46.00 to $48.00 and gave the stock an "outperform" rating in a research note on Tuesday, November 19th. Finally, TD Cowen reaffirmed a "buy" rating and issued a $58.00 price target on shares of Twist Bioscience in a research note on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $51.90.

Institutional Investors Weigh In On Twist Bioscience

Several hedge funds have recently added to or reduced their stakes in TWST. Allspring Global Investments Holdings LLC bought a new position in shares of Twist Bioscience in the second quarter valued at about $4,150,000. IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new stake in shares of Twist Bioscience during the second quarter worth approximately $402,000. Principal Financial Group Inc. boosted its holdings in shares of Twist Bioscience by 210.2% during the second quarter. Principal Financial Group Inc. now owns 122,911 shares of the company's stock worth $6,057,000 after acquiring an additional 83,287 shares during the period. Privium Fund Management B.V. acquired a new position in shares of Twist Bioscience in the second quarter valued at approximately $214,000. Finally, Victory Capital Management Inc. increased its stake in shares of Twist Bioscience by 4,133.1% during the second quarter. Victory Capital Management Inc. now owns 308,171 shares of the company's stock worth $15,187,000 after purchasing an additional 300,891 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.